Building on the success of its earlier partnership with Eden Park, XCMR has inked a second subcontract for $399,999. This funding will further the development of personal protective respirators that employ human-safe, miniature Far UV-C microplasma lamps. The award highlights the progress XCMR has made in advancing this transformative technology, designed to enhance safety for healthcare workers and the general public.
The Phase 2 subcontract follows the successful completion of XCMR’s efforts from Phase 1, which demonstrated proof of concept for applications of Far UV-C microplasma lamps. This funding will allow XCMR to refine the technology, focusing on performance optimization, scalability, and real-world applications in personal protective equipment (PPE).
XCMR’s ability to secure this Phase 2 subcontract reflects the substantial progress made during the Phase 1 project, demonstrating the potential of Far UV-C technology to protect against airborne pathogens without harm to human tissue. The DOE’s continued support for the development of Far UV-C technologies underscores XCMR’s innovation and commitment to advancing public health safety.
With this funding, XCMR will work toward commercializing the Far UV-C technology. The 24-month project will focus on scaling production, further testing, and enhancing the integration of Far UV-C lamps into personal protective respirators, making the technology viable for use in healthcare and public settings.
XCMR’s receipt of the DOE Phase 2 SBIR subcontract marks a pivotal step in the development of human-safe Far UV-C technology. With the backing of the Department of Energy, XCMR is well-positioned to bring its innovative disinfection solutions closer to market, offering critical advancements in PPE that will help safeguard public health.
